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Background: Mitral valve prolapse (MVP) is a common valve pathology and affects 
more than 176 million people worldwide. Echocardiography is the diagnostic gold standard and 
surgical intervention represents the only successful treatment when the prolapse causes severe 
regurgitation and symptoms occur. To date, there are no reliable biomarkers available for the 
identification of this pathology. MVP is a disorder characterized by extracellular matrix (ECM) 
remodelling but molecular and cellular mechanisms are not fully understood. The disruption of 
ECM tight regulation and the constitutive activation of valve interstitial cells (VIC) have been 
linked to MVP, as well as valve endothelial cell (VEC) mesenchymal transition (EndMT). 
Osteoprotegerin (OPG) is involved in a myriad of physiological and pathological processes. In 
the vascular environment, both endothelial and smooth muscle cells constitutively secrete OPG. 
In order to gain further insights into the molecular mechanisms involved in MVP progression, 
we investigated the role of OPG during EndMT and we generated a predictive model able to 
identify MVP patients with high accuracy. 
Methods: Human VECs and VICs were isolated from posterior mitral valve leaflets of 
patients who underwent mitral valve repair. β-glycerolphosphate and ascorbic acid (βGAA) 
treatments were used to promote EndMT. Immunofluorescence, Western blot, quantitative and 
digital PCR were performed to evaluate VEC and VIC phenotypes. We assessed the oxidative 
stress status measuring the oxidized (GSSG) and the reduced (GSH) form of glutathione by 
liquid chromatography-tandem mass spectrometry method. OPG plasma levels were measured 
by enzyme-linked immunosorbent assay. These biochemical variables combined with clinical 
and demographic parameters were considered to generate a logistic regression model able to 
identify MVP patients with high sensitivity and specificity. 
Results: OPG was significantly elevated (309±49.8%) in prolapsed tissues when 
compared to healthy tissues (p<0.05). We carried out an in vitro system able to force EndMT 
in isolated VECs. During EndMT, VECs showed a significant up-regulation of OPG RNA 
levels (4.1±1.3 fold vs. untreated cells; p<0.05). In addition, VECs secreted more OPG in 
comparison to untreated cells (2369±564.7 pg/µg and 923.5±261.1 pg/µg of total protein, 
respectively; p<0.05). Moreover, OPG itself triggered autocrine effects (RNA levels): collagen 
I (Col1A1, +4.0±0.6; p<0.001); collagen III (Col3A1, +3.0±0.6; p<0.01); bone morphogenetic 
protein 4 (BMP4, +2.4±0.7; p<0.05) and versican (VCAN, +3.8±0.2; p<0.001 ). Furthermore, 
OPG treatments accelerated VEC migration (area closed: 43.3±3.9% treated cells vs. 
21.8±2.6% untreated cells; p<0.001). OPG also promoted VICs proliferation (22.4% increment; 
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p<0.05) and significantly up-regulated VIC RNA levels: Col1A1 (+2.24±0.29; p<0.001); 
Col3A1 (+1.58±0.29; p<0.05); BMP4 (+1.6±0.1; p<0.05); biglycan (BGN, +1.9±0.3; p 
<0.001); VCAN (+1.5±0.2; p <0.05); metalloproteinase 2 (MMP2, +1.6±0.1; p <0.01); smooth 
muscle actin (SMA, +1.6±0.2); and OPG (+1.5±0.2; p<0.05). 
Regarding plasma analyses, both oxidative stress (GSSG/GSH ratio) and OPG levels were 
significantly higher in patients compared to control subjects (0.116±0.007 vs. 0.053±0.013 and 
1748±100.2 vs. 1109±45.3 pg/mL, respectively; p<0.001). Finally, the combination of these 
two variables with body-mass index allowed us to generate a regression model able to correctly 
identify 95% of patients and 90% of control subjects. 
Conclusions: Our results support EndMT as a possible mechanism involved in the 
pathogenesis of mitral valve degeneration. In addition, to the best of our knowledge, this is the 
first study to show a strong association between OPG, oxidative stress status and body-mass 
index in patients affected by MVP with severe regurgitation. Finally, since it is quite hard to 
believe that one single protein could discriminate two populations with high specificity and 
sensitivity, we believe that this approach could improve the identification of several signatures 
not only in mitral valve disease. As the mechanisms explaining these correlations are still 
unclear, further molecular studies along with clinical validations will be necessary to confirm 
our findings.  
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Introduzione: Il prolasso della valvola mitralica è una diffusa patologia valvolare che 
affligge più di 176 milioni di persone nel mondo. Nella pratica clinica, l’ecocardiografia è lo 
strumento diagnostico di riferimento e l’intervento chirurgico rappresenta il solo trattamento 
efficace quando il prolasso causa rigurgito severo.  Inoltre, ad oggi, non esistono biomarcatori 
circolanti utili per l’identificazione di tale patologia. Alterazioni a carico delle matrice 
extracellulare, come l’attivazione costitutiva delle cellule interstiziali e l’acquisizione da parte 
delle cellule endoteliali di un fenotipo mesenchimale (EndMT), svolgono un ruolo chiave nello 
sviluppo del prolasso mitralico. Tuttavia, ulteriori studi risultano necessari per una conoscenza 
più approfondita dei meccanismi molecolari e cellulari alla base di tale patologia. Inoltre è noto 
che l’osteoprotegerina (OPG), una glicoproteina coinvolta in numerosi processi patologici e 
fisiologici, viene rilasciata costitutivamente sia dalle cellule muscolari che endoteliali. Lo scopo 
dello studio è la valutazione del possibile ruolo dell’OPG durante l’EndMT e la creazione di un 
modello predittivo in grado di identificare con elevata accuratezza i pazienti affetti da prolasso 
mitralico. 
Metodi: Le cellule endoteliali e interstiziali sono state isolate dai lembi mitralici 
posteriori, ottenuti da pazienti sottoposti ad un intervento di riparazione della valvola mitralica. 
Allo scopo di indurre EndMT, le cellule endoteliali sono state trattate con β-glicerolofosfato e 
acido ascorbico. Tecniche di immunofluorescenza, elettroforesi, PCR quantitativa e digitale 
sono state impiegate per analizzare le caratteristiche fenotipiche di entrambi i tipi cellulari. 
Inoltre, mediante un metodo di cromatografia liquida accoppiato alla spettrometria di massa, è 
stato possibile misurare i livelli della forma ossidata (GSSG) e ridotta (GSH) del glutatione, il 
cui rapporto è un indice riconosciuto di stress ossidativo. Parallelamente, le concentrazioni 
plasmatiche di OPG sono state valutate mediante saggio ELISA. La combinazione di queste 
variabili biochimiche con parametri clinici e demografici, è stata presa in considerazione per la 
generazione di un modello statistico in grado di identificare con elevata sensitività e specificità 
pazienti affetti da prolasso mitralico. 
Risultati: Nei tessuti ottenuti dai pazienti con prolasso mitralico, i livelli di espressione 
dell’OPG risultavano significativamente più elevati (309±49.8%; p<0.05) rispetto a quelli 
riscontrati nei tessuti ottenuti da soggetti sani. Successivamente abbiamo messo a punto un 
sistema in vitro in grado di promuovere l’EndMT delle cellule endoteliali isolate da pazienti. 
Durante l’EndMT, le cellule endoteliali mostravano sia un significativo aumento dei livelli di 
RNA per l’OPG (aumento di 4.1±1.3 volte vs. cellule non trattate; p<0.05) che una maggiore 
produzione di OPG (2369±564.7 pg/µg e 923.5±261.1 pg/µg di proteine totali, rispettivamente; 
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p<0.05) rispetto alle cellule non trattate. L’OPG a sua volta determinava un aumento dei livelli 
di RNA per il collagene I (Col1A1, +4.0±0.6; p<0.001); il collagene III (Col3A1, +3.0±0.6; 
p<0.01); la proteina morfo-genetica dell'osso 4 (BMP4, +2.4±0.7; p<0.05) e il versicano 
(VCAN, +3.8±0.2; p<0.001). In aggiunta, le cellule endoteliali trattate con OPG migravano più 
velocemente rispetto a quelle non trattate (area di chiusura: 43.3±3.9% cellule trattate vs. 
21.8±2.6% cellule non trattate; p<0.001). Per quanto riguarda le cellule interstiziali, l’OPG ne 
promuoveva la proliferazione (incremento pari al 22.4%; p<0.05) e un aumento statisticamente 
significativo dei livelli di RNA per il Col1A1 (+2.24±0.29; p<0.001); il Col3A1 (+1.58±0.29; 
p<0.05); la BMP4 (+1.6±0.1; p<0.05); il biglicano (BGN, +1.9±0.3; p <0.001); il VCAN 
(+1.5±0.2; p <0.05); la metalloproteasi 2 (MMP2, +1.6±0.1; p <0.01); l’actina del muscolo 
liscio (SMA, +1.6±0.2); e l’OPG stessa (+1.5±0.2; p<0.05). Inoltre, i livelli di stress ossidativo 
(rapporto GSSG/GSH) e i livelli plasmatici dell’OPG risultavano significativamente più elevati 
nei pazienti rispetto a soggetti sani (0.116±0.007 vs. 0.053±0.013 e 1748±100.2 pg/mL vs. 
1109±45.3 pg/mL, rispettivamente; p<0.001). Combinando queste due variabili con l’indice di 
massa corporea (BMI) è stato possibile ottenere un modello di regressione logistica in grado di 
identificare correttamente il 95% dei pazienti e il 90% dei soggetti controllo. 
Conclusioni: I risultati ottenuti confermano che l’EndMT è un possibile meccanismo coinvolto 
nella patogenesi della degenerazione della valvola mitralica, inoltre per la prima volta, nei 
pazienti affetti da prolasso mitralico con rigurgito severo, è stata evidenziata una stretta 
associazione tra OPG, stress ossidativo e BMI. Tuttavia, i meccanismi alla base di tale 
associazione sono ancora poco chiari e di conseguenza si rendono necessari ulteriori studi 
molecolari e validazioni cliniche, per confermare i nostri risultati. Dal momento che risulta 
difficile poter distinguere correttamente due popolazioni considerando una sola variabile, 
riteniamo che la combinazione di più variabili possa essere d’aiuto per l’identificazione di 
nuove “firme molecolari”, non solo per le malattie a carico della valvola mitralica, ma anche 
per altre patologie.   
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BMI = body-mass index  
BMP4 = bone morphogenetic protein 4  
CD31 = platelet endothelial cell adhesion molecule  
Col1A1 = collagen I A1 
Col3A1 = collagen III A1 
dPCR = digital PCR 
ECM = extracellular matrix 
EndMT = endothelial mesenchymal transition  
GSH = reduced glutathione 
GSSG = oxidized glutathione 
MMPs = metalloproteinases 
MR = mitral regurgitation  
MVP = mitral valve prolapse  
OPG = osteoprotegerin  
qPCR = quantitative qPCR  
SMA= α-smooth muscle actin 
VCAN = versican 
VECs = valve endothelial cells  
VICs = valve interstitial cells  
VIM = vimentin  
βGAA = β-glycerolphosphate and ascorbic acid  
SDCs = syndecan receptors 
ERK = extracellular signal-regulated kinase 
GAPDH = glyceraldehyde 3-phosphate dehydrogenase  
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Hep I = heparinase I 
BGN = biglycan 
CTRL = control subjects  
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1.1 The Heart  
The heart is a specialized muscle responsible for pumping blood to the entire body. It is 
surrounded by a fibrous sac, the epicardium, and is positioned in the thoracic cavity. The heart 
is divided into a left and a right side by the septal wall and each side consists of two muscular 
chambers: the atrium and the ventricle (Figure 1.1). The right side of the heart pumps 
deoxygenated blood in the lungs (pulmonary circulation) while the left side delivers oxygen-
rich blood to the body (systemic circulation). In particular, the systemic deoxygenated blood 
through the superior and inferior vena cava arrives in the right atrium and then it is directed to 
the right ventricle. From this ventricle, the blood reach the lungs through the pulmonary artery. 
The oxygenated blood returns to the left atrium of the heart from the four pulmonary veins and 
it is directed into the left ventricle. This last chamber pumps the oxygenated blood into the 
systemic circulation towards the aorta. 
 
Figure 1.1 Illustration of the anatomy of the human heart. Adapted from 
http://nursingmedic.blogspot.com/2010/11/anatomy-of-heart.html 
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The four cardiac valves ensure the unidirectional blood flow within the heart. The 
atrioventricular (AV) valves, tricuspid and mitral, separate the atria from the ventricles on the 
right and left sides, respectively. Instead, the pulmonary and aortic valves, also known as 
semilunar valves, separate the ventricles from the great arteries. 
 
1.1.1 The Cardiac Cycle  
Myocardial contraction is due to a spontaneous generation of an electrical impulse. The 
impulse starts in the sinus node located in the superior lateral wall of the right atrium. The 
cardiac cycle, a sequence of mechanical and electrical events, mainly consists of four phases: 
atrial contraction (inflow), isovolumetric ventricular contraction, ejection (outflow) and 
isovolumetric ventricular relaxation. Commonly, these phases are also known as: systole and 
diastole. The systolic phase refers to ventricular contraction, while, the diastolic phase refers to 
ventricular relaxation (Figure 1.2).  
 
Figure 1.2 Cardiac cycle. The cardiac cycle can be mainly divided in four phases: 1) atrial systole, 
2) isovolumetric ventricular contraction, 3) ejection and 4) isovolumetric ventricular relaxation. Adapted 
from Patton KT, Thibodeau GA: Anatomy & physiology, ed. 8, St Louis, 2013.  
16  
 
The cardiac cycle has an average time of 800 ms and the cardiac valves open and close 
approximately 40 million times a year, and more than 3 billion times during the average human 
lifetime [1]. 
 
1.2 Mitral Valve 
1.2.1 Structure and Function 
The mitral valve is located between the left atrium and the left ventricle. It is a complex 
apparatus made up of several structures: the mitral annulus, the leaflets (anterior and posterior), 
the chordae tendineae and the papillary muscles (Figure 1.3). It is a dynamic three-dimensional 
system, which, by working in synchrony, allows left ventricular blood-inflow during diastole, 
whilst during systole the mitral valve isolates the left atrium from the left ventricle to ensure 
unidirectional blood-flow.  
 
Figure 1.3 Components of mitral valve apparatus. The mitral valve is made up of several 
structures: the mitral annulus, the leaflets (anterior and posterior), the chordae tendineae and the 
papillary muscles. Adapted from http://emedicine.medscape.com/article/1878301-overview 
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Normal valve functioning is crucial and depends on its integrity since it regulates the 
blood flow within the two highest-pressure chambers. However, the possible alterations of 
mechanical and cellular integrity lead to an abnormal leaflet closure with blood regurgitation 
in the left atrium, which in turn, causes loss of ventricular pressure and forward flow. 
The mitral valve has two leaflets: anterior and posterior. Both of them are attached to 
the mitral annulus at their basal ends, whereas multiple chordae tendineae emerge from the 
leaflet ventricular surfaces and attach distally to the papillary muscles. The anterior leaflet is 
characterized by a trapezoid- or dome shape and is anchored to one third of the annular 
circumference. In particular, it is attached to the fibrous portion of the mitral annulus and shares 
tissue continuity with the non-coronary leaflet of the aortic valve. The posterior leaflet is 
attached to two-thirds of the annular circumference.  
Several nomenclatures are available for the mitral valve anatomy: Classic [2], Duran [3] 
and Carpentier [4]. The European Association of Echocardiography and the American Society 
of Echocardiography, when discuss the mitral valve anatomy, adopt the Carpentier’s 
nomenclature. Accordingly, we implemented this classification. In particular, Carpentier’s 
nomenclature (Figure 1.4) divides the anterior leaflet in three regions labeled A1, A2 and A3 
corresponding to the adjacent regions of the posterior leaflet called P1, P2 and P3.  
 
Figure 1.4 Carpentier’s nomenclature of mitral valve leaflets. The anterior leaflets can be 
divided in three regions labeled A1, A2 and A3 corresponding to the adjacent regions of the posterior 
leaflet called lateral P1, P2 and P3. Adapted from Guy TS, Hill AC. Mitral valve prolapse. Annu Rev 
Med. 63:277-92; 2012.  
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The leaflets are a highly specialized structure (Figure 1.5). For each leaflet, it is possible to 
identify, from the attachment point at the annulus to the free edge, three different zones: basal, 
clear and rough. The basal zone contains nerve fibers and terminals that maintain 
electrophysiological continuity with the rest of the heart [5, 6]. The clear zone is characterized 
by a dense collagenous network and fibroblasts able to actively repair the extracellular matrix 
[7]. Finally, the rough zone, at the free edge of the leaflet, is thicker than the previous one and 
it is the main area of chordal attachment. It is also rich in glycosamiglaycans, which retaining 
water are capable of sustaining the compressive stress from coaptation [8]. 
 
Figure 1.5 Basal, clear and rough zone of mitral valve leaflets. In each leaflet, it is possible to 
identify, from the attachment point at the annulus to the free edge, three different zones: basal, clear and 
rough. Adapted from http://emedicine.medscape.com/article/1878301-overview. 
 
The mitral valve cross-sectional structure appears analogous to the aortic valve and three 
well-defined tissue layers could be identified: atrialis, spongiosa and fibrosa (Figure 1.6). Each 
layer has a different thickness, cell population, matrix composition and biomechanical features 
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that contribute to its proper function. The atrialis layer contains connective tissue that appears 
like a network of lamellar collagen and elastin. This network plays a pivotal role in adaptive 
responses to stress conditions [9]. The spongiosa is made up of glycosaminoglycans and loosely 
arranged collagen fibers [10]. Its main function is to support the compression between the outer 
layers, giving leaflet flexibility and attenuating the vibrations due to valve coaptation [11]. The 
last layer, fibrosa, is predominantly is made up of compact and aligned collagen fibers 
providing strength and stiffness to the leaflet. These fibers are also surrounded by 
glycosaminoglycans and proteoglycans in order to sustain compressive loading imposed by 
leaflet coaptation [8]. The layer distribution appears significantly different in the two leaflets. 
The thickness of the anterior one is due to a dominant fibrosa layer that helps to sustain tensile 
load without tissue disruption. The posterior leaflet appears thinner and more flexible compared 
with the anterior one [12]. 
Two cell types populate the mitral valve leaflets (Figure 1.6): 1) a monolayer of valve 
endothelial cells (VECs) which covers both the atrial and ventricular surface and 2) a 
heterogeneous population, called valve interstitial cells (VICs) that resides within the three 
layers. VECs provide a physical barrier against the hemodynamic environment. VICs represent 
the most abundant cell type within the valve and this dynamic cell population plays a pivotal 
role in the maintenance of normal leaflet architecture. In particular, VICs regulate extracellular 
matrix production and degradation during valve development and throughout the entire life [11, 
13]. These two populations reciprocally interact to ensure normal cell homeostasis [14-17]. 
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Figure 1.6 Mitral valve leaflet structure. The leaflets are organized in three different layers: 
atrialis, spongiosa and fibrosa. Endothelial cells cover both the atrial and ventricular surface while the 
interstitial cells are embedded within the layers. VECs: valve endothelial cells; VICs: valve interstitial 
cells; GAGs: glycosaminoglycans. Adapted from Levine RA et al. Mitral valve disease--morphology 
and mechanisms. Nat Rev Cardiol. 12(12):689-710; 2015. 
 
1.3 Mitral Valve Diseases 
 Abnormalities in the mitral valve complex prevent normal leaflet coaptation and may 
cause blood regurgitation in the left atrium during systole. This pathological condition is known 
as mitral regurgitation (MR). MR due to structural or degenerative abnormalities is called 
primary MR, whereas, the secondary MR is a consequence of left ventricle alterations (such as 
myocardial infarction) [18, 19]. Another mitral disease, mostly common in elderly patients, is 
the mitral valve stenosis. It is characterized by a prominent calcification of mitral annulus and 
leaflets causing left ventricular inflow obstruction. This condition, however, is mainly caused 
by a rheumatic disease [19, 20]. 
 
1.3.1 Primary MR 
Primary MR is mainly due to a degenerative mitral valve disease, defined as 
myxomatous degeneration characterized by distinctive histological changes with elongated and 
21  
 
redundant chordal apparatus [21]. Myxomatous mitral valve degeneration represents the 
principal cause of mitral valve prolapse (MVP) and it is one of the most common heart valve 
diseases in humans. MVP has a prevalence of 2-3% in the general population and affects more 
than 176 million people worldwide [11, 22]. Interestingly, the pathology is equally distributed 
between men and women [11] and patients with prolapse have significantly lower body-mass 
index (BMI) and waist-to-hip ratio than healthy subjects [22]. 
The prolapse may be identified when one, both, or a portion of the leaflets extend above 
the plane of the atrioventricular junction during left ventricular systole [23-25] causing blood 
flow regurgitation in the left atrium. It has been reported that prolapse involves the posterior 
leaflet in 67% of cases, the anterior one in 10% of cases and both leaflets in 23% of cases [26]. 
In the normal mitral valve, the ratio between anterior and posterior leaflet surface area is 2:1. 
However, this ratio appears altered in MVP due to an enlargement of all portions of the posterior 
leaflet. In addition, the myxomatous degeneration increases the mitral annular size and causes 
thinning, elongation and rupture of chordae tendineae [26-28].  
In myxomatous MVP, increased expression of proteoglycans, which foster the leaflet 
thickening, and metalloproteinases (MMP), which contribute to the fragmentation of collagen 
and elastin fibers, disrupt the well-organized leaflet structure [29-32]. Indeed, Rabkin et al.[30] 
have observed an expansion of the spongiosa, strongly positive for proteoglycans, loosened 
collagen in the fibrosa and elastin fragmentation in atrialis. The authors have also identified an 
increased interstitial cell density in the spongiosa layer. These extracellular matrix changes 
were further confirmed by Sainger et al. [33] (Figure 1.7). 
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Figure 1.7 Morphological features of normal and myxomatous mitral valves. (A) Composite 
photomicrographs of sections of normal and diseased human mitral valve leaflets (transverse sections). 
Movat Pentachrome staining:  proteoglycan (blue), collagen (yellow), muscle (red). FE, free edge; VS, 
ventricular surface; AtS, atrialis surface. (B) Representative image of Hematoxylin and Eosin staining 
(H&E) section of the mitral valve spongiosa layers of control and MVP patient and relative number of 
valve interstitial cells per field. (C) Quantification of total cell number within selected fields of the 
spongiosa layers. Bar graph: 50 µm *p < 0.05. Adapted from Sainger, R. et al. Human myxomatous 
mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation. J Cell 
Physiol, 227(6): 2595-604. 2012. 
 
Another peculiar feature in MVP, is the VIC activation. In particular, VICs acquire a 
myofibroblast-like phenotype, characterized by increased expression of alpha-smooth muscle 
actin (SMA) [30, 34] (Figure 1.8). 
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Figure 1.8 Accumulation of myofibroblast-like interstitial cells in myxomatous mitral 
valves. Interstitial cells acquire a myofibroblast-like phenotype characterized by of alpha-smooth 
muscle actin (SMA) espression. Scale bar 50 µm. Adapted from Rizzo, S. et al. TGF-beta1 pathway 
activation and adherens junction molecular pattern in nonsyndromic mitral valve prolapse. Cardiovasc 
Pathol, 24(6): 359-67; 2015.  
 
 The activated VICs are responsible for increased levels of different proteolytic enzymes, 
including MMPs, which are directly involved in collagen and elastin degradation. In particular, 
it has been reported that activated VICs express high levels of MMP-1, MMP-13 [30].  
 
1.3.1.1 Barlow’s vs. FED 
In the 1980s, based on clinical patterns, echocardiography findings and gross surgical 
appearances [35], Carpentier classified the myxomatous degenerative mitral valve disease into 
two subtypes (Table 1.1). Barlow’s disease (alternatively known as billowing mitral valve or 
diffuse myxomatous degeneration) is characterized by excessive and diffuse accumulation of 
glycosaminoglycans, whereas fibroelastic deficiency (FED) by extremely thin leaflets and 
chordae [35-39]. Echocardiography is currently the principal diagnostic tool used to distinguish 
Barlow’s and FED. Patients with Barlow’s disease often have a long clinical history of MR and 
are usually younger compared with FED. In contrast, FED patients experience chord rupture 
and flail leaflet [37, 38, 40]. 
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Table 1.1 Macroscopic and microscopic characteristics of Barlow and FED diseases  
 
Macroscopically, Barlow’s disease is characterized by thickened leaflets with a soft 
and gelatinous consistency, while, microscopically, the fibrosa appears expanded due to an 
alteration in the composition of glycosaminoglycans and proteoglycans. Collagen and elastic 
fibers appear fragmented and less dense than normal. In addition, the chordae tendineae are 
frequently characterized by myxomatous degeneration, which may represent the background 
for chordae rupture. Moreover, a superficial plaque is often observed, predominately on the 
ventricular side, characterized by the accumulation of stellate and spindle shaped cells. This 
plaque is a secondary feature, probably due to flow abnormalities [41] (Figure 1.9A). 
In contrast, FED patients show a preserved three-layer leaflets structure. This 
pathological condition is characterized by decreased connective tissue, collagen, elastin and 
proteoglycans. The leaflets appear thin, smooth and translucent without excess tissue. 
Sometimes, a moderate mitral annulus dilatation and thin/elongated chordae may be found [11, 
41] (Figure 1.9B). An important feature of FED is the myxomatous degeneration and 
thickening localized in focal areas within the flail scallop, mainly in the posterior leaflet (P2 
segment) [39]. The etiology of connective tissue deficiency in FED patients is unknown but 
may be age-related.  
Barlow's Disease FED Disease
Age at Diagnosis < 50 years > 50 years
Valve Morphology
Annular Dilatation (+++) (+)
Leaflets Thickened (++) Thin
Excess tissue (+++) No excess tissue 
Choardae Heterogeneous Thin
Elongated Ruptured
Lef ventricular 
dilatation
N/A N/A
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The surgical approaches for Barlow’s and FED disease are very different. It is not clear 
whether the Barlow’s and FED are two histopathological features of the same syndrome or two 
genetically distinct entities. 
 
Figure 1.9. Morphological characteristics of Barlow and FED diseases. Adapted from 
Carpentier A. et al. Carpentier’s Reconstructive Valve Surgery from Valve Analysis to Valve 
Reconstruction.  
 
1.3.2 Secondary MR 
Secondary MR is characterized by left ventricle dilatation that results in leaflet tethering 
and annular dilation preventing correct coaptation [42]. This pathological condition may be due 
to either ischemic or non-ischemic causes. Ischemic secondary MR is a consequence of 
myocardial infarction [43], while non-ischemic secondary MR is due to long lasting 
hypertension or idiopathic dilated cardiomyopathy [43]. 
Emerging evidence suggests a possible involvement of the endothelial to mesenchymal 
transition (EndMT) in the progression of MR [9, 44]. It is known that a subset of endothelial 
progenitor cells are able to undergo EndMT. In particular, during heart valve development, the 
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endothelial cells lose cell-cell contact, transiently upregulate SMA and migrate into the 
interstitium to populate the nascent valve; while in adult valves the EndMT may contribute to 
replenish the VIC population throughout the entire lifetime [45] (Figure 1.10).  
 
Figure 1.10 Endothelial to mesenchymal transition in mitral valve. Schematic representation of 
endothelial cell activation and their migration in the interstitium. CD31: platelet endothelial cell 
adhesion molecule; EndMT: endothelial to mesenchymal transition; SMA: α-smooth muscle actin; 
VECs: valve endothelial cells; VICs: valve interstitial cells. 
 
In a recent work [9], ovine mitral valve leaflets were exposed to mechanical tethering, 
in order to mimic the mechanical stretch imposed on the mitral leaflets after myocardial 
infarction. Stretched leaflets showed positive staining for platelet endothelial cell adhesion 
molecule (CD31), an endothelial cell marker, and for SMA. The localization of SMA-positive 
cells, within and on the surface of the leaflets, represents not only the VIC activation but also 
that endothelial cells underwent EndMT [9].  
These findings highlight that EndMT could be an adaptive mechanism that may 
contribute to increased mitral leaflet thickness and area, not only in secondary MR but also in 
the pathogenesis and progression of other mitral valve diseases.  
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1.3.3 Osteoprotegerin: a new player in mitral valve disease? 
Osteoprotegerin (OPG) is a protein belonging to tumour necrosis factor (TNF) family. 
Several studies underlined a correlation between this protein and different pathological 
conditions such as coronary artery syndromes [46-48], aortic valve stenosis [49-51] and 
myocardial infarction [52], focusing only on the TNF superfamily. OPG is also linked to cardio-
metabolic disorders [53] and increased cardiovascular and over-all mortality [54, 55]. It has 
been shown that transforming growth factor β (TGF-β), a well-known player in myxomatous 
MVP pathogenesis [56], increases oxidative stress status [57] as well as OPG production and 
secretion [58]. In the vasculature environment, both endothelial and smooth muscle cells 
constitutively secrete OPG [59, 60]. A recent study also highlighted the link between OPG and 
oxidative stress status on endothelial cells [61]. 
OPG, is a protein encoded by TNFRSF11B gene localized on 8q24.12 chromosome. It 
is a secretory glycoprotein composed of 401 aminoacids arranged into seven structural domains. 
In particular, cysteine rich domains (1-4) are essential for osteoclastogenesis inhibition, two 
death domains (5-6) which mediate apoptosis and an heparin binding domain (7) capable of 
interacting with heparin-sulphate proteoglycans (Figure 1.11). 
 
Figure 1.11 Osteoprotegerin structure. Protein of 401 aminoacids organized in seven structural 
domains. 
 
OPG is mainly known as a decoy receptor for receptor activator of nuclear factor kappa-
B ligand (RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), 
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regulating different processes (i.e. bone resorption and cell apoptosis) (Figure 1.12). 
Interestingly, as previously reported, OPG may interact with heparin-sulphate proteoglycans, 
such as syndecan receptors. The syndecan family is made up of four isoforms expressed in 
different cell type and involved in many processes such as cell proliferation, differentiation, 
adhesion and migration [62] (Figure 1.12). 
 
Figure 1.12 Schematic representation of OPG/TRAIL/RANKL/SYNDECAN system. 
OPG: osteoprotegerin; R: receptor; RANK: receptor activator of nuclear factor kappa-B; RANKL: 
receptor activator of nuclear factor kappa-B ligand; TRAIL: TNF-related apoptosis-inducing ligand. 
Adapted from Bernardi S. et al. Roles and Clinical Applications of OPG and TRAIL as Biomarkers in 
Cardiovascular Disease. Biomed Res Int. 2016. doi: 10.1155/2016/1752854. 
 
1.3.4 Diagnosis 
Two dimensional (2D) echocardiography represents the gold standard for diagnosis and 
assessment of patients presenting MR [18, 19]. It is a non-invasive imaging test able to provide 
detailed information about the structure and function of the mitral valve apparatus, the left 
ventricle and the atrium.  
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MVP represents a particular feature of mitral valve disease frequently associated with 
MR. During the echocardiographic evaluation, a single or bi-leaflet displacement, of at least 2 
mm above the mitral annulus plane, define MVP. However, the diagnosis of MVP should also 
consider the evaluation of the structural changes of the entire mitral valve apparatus. A prolapse 
with leaflet thickening greater than 5 mm is defined ‘classic’, whereas a minor degree of 
thickening is regarded as ‘non-classic’ [63]. 
According to American guidelines [64], the regurgitated volume, evaluated through Doppler 
echocardiography, should also be taken into consideration in order to identify the severity of 
MR. In particular, a regurgitated volume of less than 30 mL/beat, between 30-60 mL/beat and 
more than 60 mL/beat corresponds to mild, moderate and severe MR, respectively [64, 65]. 
In current clinical practice, the use of three-dimensional (3D) echocardiographic (3DE) 
imaging represents a major innovation in cardiovascular ultrasound. Advancements in 
computer and transducer technologies make possible a real-time 3DE acquisition and allow the 
identification of cardiac structures from any spatial point of view [66]. The combination of 2D 
and 3D echocardiography provides detailed morphological and functional assessment, whereas 
Doppler echocardiography evaluates hemodynamics. 
 
1.3.4.1 Biomarkers 
Biomarkers have been defined by Hulka et al. [67] as “cellular, biochemical or molecular 
alterations that are measurable in biological media such as human tissues, cells, or fluids.” To 
date, a broader definition has been proposed, taking into account all biological characteristics 
objectively measured as indicators of physiologic or pathologic processes [68]. In the clinical 
practice, they represent an important tool for a better diagnosis and prognosis of a specific 
pathological condition. Although, 2D echocardiography is the gold standard for MR diagnosis, 
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circulating biomarkers could provide valuable insights into the improvement of MVP patient 
stratification. 
However, specific circulating biomarkers for MR have been investigated only in few 
studies and, in most cases, the investigators used animal models. In particular, in a recent study 
Deroyer et al.[69] have shown that apolipoprotein-A1 was an independent predictor of MR 
severity. It has also been shown that altered antioxidant defense systems and an increase of lipid 
peroxidation markers were disarranged in MVP patients, with severe MR, in comparison to 
healthy subjects [70]. Recently, a new class of circulating biomarkers, called non-coding RNAs, 
have emerged. In particular, microRNAs represent the most studied. Unfortunately, these 
circulating microRNAs have only been evaluated in canine models [71, 72]. Therefore, further 
studies, which may identify new specific molecular signatures, are needed to improve clinical 
practice. 
 
1.4 Pharmacological and Surgical Treatments  
1.4.1 Primary MR 
To date, there are no recommended pharmacological treatments for patients with 
minimal symptom of primary MR or completely asymptomatic. Nevertheless, beta-blockers 
and angiotensin-converting enzyme inhibitors may be used for stress reduction on the valve 
[73], thus delaying surgical intervention. However, surgical intervention (repair or replacement) 
is the only available option when MR becomes severe or major symptoms occur [18, 19] .  
Surgical repair has significant advantages in comparison to complete replacement. In 
particular, repair techniques offer lower operative mortality [74-78], preserve left ventricular 
function and give rise to fewer complications, such as thromboembolism, anticoagulant-related 
hemorrhage and endocarditis, [29, 75, 79-82]. According to the type and location of the mitral 
lesions, resection of the flail and prolapsed leaflet segment or reconstructive techniques, using 
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artificial chords, may be performed to treat primary MR [83]. The durability of mitral valve 
repair is higher for the posterior prolapse in comparison to the anterior and the bi-leaflet 
prolapse [84]. However, surgeons’ expertise is very important for the long-term success of 
mitral repair and to guarantee low operative mortality rates (less than 1%) [18, 38]. The standard 
surgical approach, characterized by sternotomy under extracorporeal circulation and direct 
repair in according to Carpentier’s method, is the treatment of choice. This method consists in 
a quadrangular or triangular resection of the prolapsed segment, chordal shortening, and ring 
replacement [85] (Figure 1.13). 
 
 
Figure 1.13 Mitral valve repair. (A) Typical anatomy associated with mitral valve regurgitation 
showing prolapse of the P2 segment of the posterior leaflet. (B) Triangular resection of prolapsed P2 
segment. (C) Quadrangular resection and ring placement. Adapted from Guy TS, Hill AC. Mitral valve 
prolapse. Annu Rev Med. 63:277-92; 2012.  
 
The standard surgical approach is not indicated for elderly patients with multiple co-
morbidities [86, 87]. In this case, the surgeons use a minimally invasive technique without 
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extracorporeal circulation, known as percutaneous transcatheter mitral valve repair [86]. To 
date, several transcatheter devices are under investigation but the most adopted one is the 
MitraClip System [86]. Anterior and posterior leaflets are clipped together to create a double 
orifice within the mitral valve [86] (Figure 1.14). 
 
Figure 1.14 MitralClip device. MitraClip device (left), the MitraClip deployed on the mitral valve 
leaflets (middle), and a “double-orifice” within mitral valve (right). Adapted from Chiam P, Ruiz C. 
Percutaneous transcatheter mitral valve repair: a classification of the technology. JACC Cardiovasc 
Interv. 4(1):1-13; 2011. 
 
The EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) is a recent 
randomized trial that compared the MitralClip device to conventional surgery [88]. The study 
highlighted that patients treated with MitraClip had significant residual MR in comparison to 
standard surgery [88]. Nevertheless, the use of MitraClip is considered safer and results in 
similar clinical outcome improvements to standard surgery [88]. However, the results of a 5 
year follow-up indicated the need of an additional surgery to correct residual MR in patients 
treated with Mitralclip [89]. Therefore, in the USA, the MitralClip is only approved for patients 
with primary MR and severe symptoms presenting a high risk for MV surgery. In Europe, 
however, the MitralClip can still be used at the surgeon’s discretion [86]. 
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1.4.2 Secondary MR 
To date, the same pharmacological treatment recommended for left ventricular 
dysfunction (i.e. beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor 
antagonisms and aldosterone antagonisms) are the most effective available treatments for 
patients with secondary MR [18]. However, if patients are unresponsive to the medical 
treatments, surgical intervention is required. 
The most common surgical approaches are mitral valve annuloplasty (repair) and 
replacement [43] but the best surgical treatment is still not clear [84]. Annuloplasty renews the 
correct leaflet coaptation, by reshaping the correct annular 3D structure, thus eliminating the 
acute mitral regurgitation symptoms [86]. Randomized trials [90, 91] have recently shown that 
clinical outcomes between repair and replacement in patients with secondary MR are 
equivalent. In addition, patients who underwent mitral replacement experienced a lower rate of 
MR recurrence, after 2 years, compared with those who underwent annuloplasty [90, 91]. In 
Europe, the secondary MR is the most common indication for MitralClip use. However, the 
system has the same limitations as previously described for primary MR. 
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2. AIMS 
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Mitral valve prolapse (MVP) is a debilitating disease with an estimated prevalence of 
2-3% affecting more than 176 million people worldwide [11, 22]. The pathology was first 
described in the late 1800s [11], nevertheless, the major risk factors have not been identified 
yet [92]. The surgical intervention represents the only available option when the prolapse causes 
severe regurgitation and symptoms occur [18, 19]. The echocardiography is the diagnostic gold 
standard and, up to now, there are no reliable biomarkers available for the identification or the 
progression of this pathology.  
MVP is a disorder characterized by extracellular matrix (ECM) remodeling. In 
particular, diseased mitral valves display an overexpression of bone morphogenetic proteins 
(i.e. BMP2 and 4), metalloproteinases (MMPs) and proteoglycans (i.e. biglycan and versican) 
[30, 33, 93]. A peculiar feature is the activation of valve interstitial cells (VIC). The activated 
VICs contribute to ECM alterations through an increase of proteolytic enzymes, including 
MMPs. Recently, MVP pathogenesis has been linked to valve endothelial cell (VEC) 
mesenchymal transition (EndMT) [9, 44]. Briefly, the endothelial cells lose their cell-cell 
contacts, acquire an activated phenotype and migratory properties. This process, in combination 
with ECM alterations, could be considered an adaptive mechanism that contributes to disease 
progression. 
Osteoprotegerin (OPG) is a glycoprotein belonging to tumor necrosis factor family. In 
the vasculature environment, both endothelial and smooth muscle cells constitutively secrete 
OPG [59, 60]. OPG is a decoy receptor for receptor activator of nuclear factor kappa-B ligand 
(RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), regulating 
multiple processes (i.e. bone resorption and cell apoptosis). OPG may also interacts with 
syndecan receptors, regulating other cellular processes (i.e. proliferation, differentiation and 
migration). 
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Given the background, the general aim of the study is to provide new details for the 
molecular mechanisms, underlying the disease progression. In particular, we evaluated EndMT 
in patients affected by mitral valve prolapse with severe regurgitation. Afterwards, we studied 
the potential involvement of OPG in EndMT and its effect(s) on mitral valve endothelial and 
interstitial cells. Finally, we investigated if OPG could be a potential circulating biomarker, in 
order to provide helpful insights for better MVP patient stratification. Therefore, the second 
aim was to generate a predictive model able to discriminate MVP patients from healthy subjects 
with high sensitivity and specificity.  
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3. MATERIALS AND METHODS 
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3.1 Patient Population  
This observational study was approved by the Institutional Review Board of Centro 
Cardiologico Monzino IRCCS and conformed to the ethical guidelines of the Declaration of 
Helsinki (1975).Written informed consent has been obtained from patients undergoing posterior 
mitral valve repair (MVR) and also from control subjects. We enrolled patients candidates for 
MVR due to posterior or anterior mitral valve prolapse (MVP) with severe regurgitation. Blood 
samples were obtained the day before surgery and mitral valve specimens were collected in 
saline solution immediately after mitral valve resection.  
The preoperative inclusion criteria taken into consideration were: need for elective, 
isolated surgical procedure; patients over 18 year of age, an ejection fraction of > 30%, a normal 
sinus rhythm and no history of atrial fibrillation. Patients with bicuspid aortic valve, premature 
menopause and/or osteoporosis, previous aortic or mitral valve surgery, rheumatic heart 
disease, endocarditis, active malignancy, chronic liver failure, calcium regulation disorders 
(hyperparathyroidism, hyperthyroidism, and hypothyroidism), and chronic or acute 
inflammatory states (sepsis, autoimmune disease, and inflammatory bowel disease) were 
excluded.  
Control subjects has been screened from those attending the Clinic for Global control of 
Cardiovascular Risk at Centro Cardiologico Monzino, IRCCS. The inclusion criteria were: over 
18 years of age, normal sinus rhythm, no electrocardiographic alterations, no history of atrial 
fibrillation, cardiovascular risk factors similar to that of MVP patients but without 
cardiovascular diseases. In collaboration with the University of Pennsylvania, three healthy 
mitral valve leaflets were obtained from the Penn Cardiac Bio-registry.  
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3.2 Blood Sampling 
Peripheral blood samples were drawn from the antecubital vein of patients (before 
surgery) and control subjects (on fasting stomach), using 2 tubes containing EDTA (9.3 mM; 
Vacutainer Systems, Becton Dickinson, Franklin Lakes, NJ, USA).  
The first Vacutainer, containing whole blood, was kept on ice all the time. An aliquot was 
combined (1:1) with 10% trichloroacetic acid (TCA - Sigma-Aldrich, St Louis, MO, USA) and 
1 mM EDTA and then soted at -80°C until oxidative stress measurements. 
The second tube was used for plasma isolation. The tube was centrifuged at 3000 x g for 
10 min at 4°C (within 30 min after being drawn) and the resulting plasma was aliquoted and 
stored at -80°C. 
 
3.3 Endothelial and Interstitial Cell Isolation 
Isolation of both mitral endothelial (VEC) and interstitial cells (VIC) was performed 
using a method described by Poggio et al. [94]. Briefly, mitral leaflets were placed in 2 mg/mL 
type II collagenase (Worthington Biochemical Corp., NJ, USA) in Advanced Dulbecco’s 
modified Eagle’s medium (DMEM – Thermo Scientific, MA, USA) containing 10% foetal 
bovine serum (FBS - Thermo Scientific, MA, USA) 1% Penicillin (Thermo Scientific, MA, 
USA), 1% Streptomycin solution (Thermo Scientific, MA, USA) and incubated for 20 min at 
37°C. Loosened endothelial layer was removed by wiping the leaflet surfaces with sterile cotton 
swabs. The resulting cells were washed and isolated using Dynabeads® conjugated with 
platelet endothelial cell adhesion molecule (CD31 – Thermo Scientific, MA, USA), an 
endothelial marker, and cultured in M200 media supplemented with low serum growth 
supplement (LSGS - Thermo Scientific, MA, USA) on 0.1% gelatine (Sigma-Aldrich, St Louis, 
MO, USA) coated tissue culture plate. Afterwards, tissues were finely minced and dissociated 
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with type II collagenase (2 mg/mL) overnight at 37°C. The resulting VICs were seeded in tissue 
culture plates in supplemented advanced DMEM media. All the experiments were performed 
on cultured cells between their second and fifth passages. Cells were left untreated or treated 
with 10 mM β-glycerophosphate and 50 mg/mL ascorbic acid (βGAA - Sigma-Aldrich, St 
Louis, MO, USA) for 6 and 12 days or  with 50 ng/mL osteoprotegerin (OPG - Prospecbio, 
USA) for 6 and 12 days unless specified elsewhere. β -glycerophosphate and ascorbic acid are 
able to induce in vitro endothelial mesenchymal transition [44]. 
 
3.4 RNA Extraction 
RNA was extracted from VECs and VICs using the Total RNA Purification Plus Kit 
(Norgen Biotek Corp., Canada). Briefly, the cell monolayer was washed with phosphate-
buffered solution (PBS – Euroclone, Milan, Italy) and then were lysed using a specific buffer 
provided in the kit. Following this, genomic DNA was removed and total RNA was purified 
using provided columns. RNA was quantified with Nanodrop (TECAN pro infinite M200) and 
used for two steps PCR amplification with TaqMan Reverse Transcription Reagent kit (Thermo 
Scientific, MA, USA). Total RNA (1 mg) was converted into complementary DNA (cDNA). 
 
3.5 Real-Time and Digital PCR 
Real Time PCR (qPCR) was performed on ABI Prism 7900 HT (Applied Biosystems), 
according to the manufacturer’s instructions, to evaluate the relative expression of specific 
genes. The analysis was conducted with software SDS2.4 (Thermo Scientific, MA, USA) and 
gene expression levels were normalized with glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). 
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Digital PCR (dPCR) was carried out on a QuantStudio™ 3D Digital PCR System 
platform made up of the QuantStudio™ 3D Instrument, the Dual Flat Block GeneAmp® PCR 
System 9700 and the QuantStudio™ 3D Digital PCR Chip Loader (Thermo Scientific, MA, 
USA). dPCR manufacturer’s instructions were followed and analysis was performed using 
QuantStudio® 3D AnalysisSuite™ (Thermo Scientific, MA, USA). Primers labelled with 
FAM® or VIC® dyes were used to evaluate the expression of targeted genes and the 
housekeeping gene respectively. Gene expression levels were normalized with ribosomal 
protein large P0 (RPLP0). The primers used are listed in Appendix A, Table A1.  
 
3.6 Immunofluorescence 
Immunofluorescence staining was performed to evaluate cell protein expression using 
specific antibodies against the platelet endothelial cell adhesion molecule (CD31 - Santa Cruz 
Biotechnology, Dallas, USA), α-smooth muscle actin (SMA- Abcam, Cambridge, United 
Kingdom) and vimentin (VIM - Cell Signaling Technology, Danvers ,USA). VICs and VECs 
were cultured in special immunofluorescence chambers (IBIDI GmbH, German) and fixed with 
paraformaldehyde (PFA - Sigma-Aldrich, St Louis, MO, USA) 4% for 15 minutes at room 
temperature. Cells were subsequently permeabilized with cold methanol for 10 minutes at room 
temperature and then incubated with blocking solution for 1 hour at room temperature. After 
washing, cells were incubated with the appropriate primary antibody overnight at 4°C protected 
from light. Cells were then washed with cold PBS and incubated with the secondary antibody 
for 2 hours at room temperature and protected from light. After washing, Vectashield mounting 
media with DAPI (Vector Laboratories, CA, USA) was added in order to detect cell nuclei. 
Zeiss Apotome microscope was used to capture the images. 
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3.7 Western blot  
Western Blot analysis was carried out to assess protein expression using specific 
antibodies against phosphorylated syndecan 4 (pSDC4 - Santa Cruz Biotechnology, Dallas, 
USA - observed band molecular weight (MW) 24 kDa), SDC4 (Santa Cruz Biotechnology, 
Dallas, USA - observed band MW 24 kDa), Heparinase I (Hep I - Sigma-Aldrich, St Louis, 
MO, USA), phosphorylated extracellular signal-regulated kinase (pERK - Cell Signaling 
Technology - observed band MW 42/44 kDa), ERK (Santa Cruz Biotechnology, Dallas, USA 
- observed band MW 44 kDa), metalloproteinase 9 (MMP9 - Santa Cruz Biotechnology, Inc - 
observed band MW 89/92 kDa), osteoprotegerin (OPG - R&D Systems, Inc., Canada, USA), 
transforming growth factor beta 1 (TGFβ-1 - Cell Signaling Technology, Danvers, USA) and 
GAPDH (Cell Signaling Technology, Danvers, USA - observed band MW 37 kDa). 
Briefly, after the treatments with or without TGβ1, OPG and Hep I, cells were collected 
and lysed in cell lysis buffer supplemented with a protease and or phosphatase inhibitor cocktail 
(Thermo Scientific, MA, USA). Total protein concentration was quantified with BCA kit 
(Thermo Scientific, MA, USA). Afterwards, proteins were separated on Bolt™ 4-12% Bis-Tris 
Plus Gels (Thermo Scientific, MA, USA) transferred onto nitrocellulose membrane and blocked 
with skim milk (Sigma-Aldrich, St Louis, MO, USA). Target proteins were detected by 
membrane incubation overnight at 4 °C with specific primary antibodies. Then the membranes 
were washed and incubated with peroxidase-conjugated secondary antibodies for another 2 h. 
Finally, the membrane was washed to remove any excess secondary antibody and incubated 
with Pierce™ ECL Western Blotting Substrate (Thermo Scientific, MA, USA) to detect specific 
bands. The images were acquired with the Alliance Mini 2M (UVITEC, Cambridge), and 
densitometric analysis of membranes was performed using the software ImageJ (Version 1.48m 
– National Institute of Health). 
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3.8 Collagen Assay 
The Sircol Soluble Collagen Assay (Biocolor, United Kingdom) is a quantitative dye-
binding method that has been designed for the analysis of soluble collagens released into cell 
culture medium during cell growth and/or specific cell treatments. In accordance with the 
manufacturer's instructions, we quantified total soluble collagen in cell culture supernatants 
after OPG treatment. Briefly, VECs or VICs were incubated in serum free DMEM with or 
without OPG for different time points (24 and 48 hours). At the end of treatment, the cell culture 
supernatants were collected and incubated with Sircol Dye Reagent in order to permit collagen-
dye complex formation. Then unbound dye was removed from the surface of the complex using 
ice-cold Acid-Salt Wash Reagent. Finally, all the bound dye was dissolved with Alkali Reagent. 
The samples were read at 555nm and the results were expressed as a ratio between collagen 
concentration/ total protein (ng/ug).  
 
3.9 Zymography 
MMP9 activity was detected by gelatin zymography using cell culture supernatant 
collected after OPG treatment, following manufacturer’s instructions. Briefly, samples are run 
on Novex® Zymogram Gelatin Gel (Thermo Scientific, MA, USA) under non reducing 
conditions. After electrophoresis, the gel was renatured with Zymogram Renaturing Buffer and 
then incubated with Zymogram Developing Buffer. The gel was stained with Coomassie 
brilliant blue G-250 (Sigma-Aldrich, St Louis, MO, USA) and destained in water in order to 
identify regions of protease activity that appear as clear bands on a dark blue background where 
the protease has digested the substrate.  
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3.10 Flow Cytometry Analysis 
Flow cytometry analysis was performed on 1% PFA fixed cells. For intracellular staining, 
cells were permeabilized with cold methanol for 30 minutes at 4°C followed by incubation with 
specific antibody tetramethylrhodamine isothiocyanante (TRITC)-conjugated. A total of 
10,000 events per sample were acquired on a BD FACS Calibur. Cytometer performances were 
checked by daily running BD Cytometer Setup and Tracking Beads. Data were reported as 
mean fluorescence intensities (arbitrary units), calculated from fluorescence histograms for 
population or as percentage of cells positive for the analysed antigens. All the data were 
analysed with FlowJo vX.0.7 Software. 
 
3.11 Migration Assay 
The directional cell migration assay was performed using 24-well plate with culture 
inserts (IBIDI GmbH, German). Briefly, VECs and VICs were seeded in the inserts of the 24-
well system and allowed to adhere overnight. Inserts were removed to create a cell-free gap of 
approximately 500 µm, and cells were allowed to migrate for 24 hours at 37°C and 5% CO2 in 
the presence of OPG or in the medium alone. Every 3 hours pictures of the gaps were taken 
with the ZEISS ApoTome and ImageJ (Version 1.48m – National Institute of Health) was used 
to analyse the cell free area. 
 
3.12 Osteoprotegerin Quantification 
Blood was collected form patients and control subjects and processed to obtain plasma. 
OPG plasma levels were evaluated by enzyme-linked immunosorbent assay (ELISA - R&D 
Systems, Inc., Canada, USA) in accordance with the manufacturer’s instructions.  
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3.13 Oxidative Stress Measurements 
The oxidative stress evaluation was assessed by a previously developed and validated 
LC-MS/MS method [95]. The ratio between oxidized (GSSG) and reduced (GSH) form of 
glutathione (GSSG/GSH) is a well-recognized index. GSSG and GSH levels were measured on 
whole blood with added 10% TCA in 1 mM EDTA solution to precipitate proteins.  
 
3.14 Proliferation Assay 
Cells were seeded in 96 well plate and the day after were incubated with or without OPG 
for 24 hours. At the end of the treatments, the medium was removed and the 3-(4, 5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT - Sigma-Aldrich, St Louis, MO, 
USA) solution (0.5 mg/ml) was added into each wells and incubated at 37°C, 5% CO2 for 2 
hours. Then the supernatant was discarded and dimethylsulfoxide (DMSO - Sigma-Aldrich, St 
Louis, MO, USA) was added into each wells. The corresponding absorbance value was 
observed using the microplate reader (TECAN pro infinite M200) at dual wavelength of 590 
nm and 620 nm. 
 
3.15 Statistical Analysis  
Data were analysed using IBM SPSS statistic software (version 22) and Graph Pad Prism 
software (version 6). Continuous variables were expressed as mean ± standard error (SEM). 
For comparisons of continuous and categorical data, the parametric T-test and the Pearson Chi-
square test were used respectively.  
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3.15.1 Binary logistic regression model 
Continuous variables are summarized as mean ± SE, except for age, which is represented 
as mean [minimum, maximum], while categorical variables are summarized as frequency and 
percentage. 
For data analysis, the Mann-Whitney test was performed between MVP and control classes on 
continuous variables, while Fisher's exact test on discrete ones.  
Finally, taking into account the OPG measurement and GSSG/GSH ratio together with 
body mass index (BMI), several logistic regression procedures were implemented in order to 
identify a classification rule, capable of predicting outcomes with the highest accuracy. 
The logistic model is: 
 = ′	′
 =
1
1 + 

 
Where, p = probability to have MVP, x1 = OPG measurement (in pg/mL), x2 = GSSG/GSH 
ratio and x3 = BMI (Kg/m2). 
A receiver operating characteristic (ROC) curve was plotted for each model and performances 
were evaluated by comparing areas under the ROC Curve (AUC). 
  
47  
 
 
 
 
 
4. IN VITRO STUDY 
 
 
 
 
 
 
 
The data reported in the following chapter have been published as: 
Songia P et al. Mitral valve endothelial cells secrete osteoprotegerin during endothelial 
mesenchymal transition. Journal of Molecular and Cellular Cardiology. 23;98:48-57; 2016. 
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4.1 Human mitral valve endothelial and interstitial cell 
characterization 
We enrolled and collected specimens from twenty-five patients affected by posterior 
mitral valve prolapse (MVP) who underwent surgical repair. From the collected specimens, we 
isolated endothelial (VECs) and interstitial cells (VICs). At phase contrast microscopy, VECs 
showed classical cobblestone morphology, while VICs a spindle shape one (Figure 4.1A). In 
addition, immunofluorescence staining revealed that VECs were positive for platelet 
endothelial cell adhesion molecule (CD31) at the cell-cell borders, vimentin (VIM) throughout 
the cytoplasm but not for α-smooth muscle actin (SMA) (Figure 4.1A). In contrast, VICs were 
positive for SMA, VIM and negative for CD31 (Figure 4.1B). 
 
Figure 4.1 Human mitral valve endothelial and interstitial cell characterization. (A-B) 
Phase contrast imaging and immunofluorescence staining for platelet endothelial cell adhesion molecule 
(CD31 – Red), smooth muscle actin (SMA – Green), vimentin (VIM – Green) and 4',6-diamidino-2-
phenylindole (DAPI, for nuclei detection – Blue), in human isolated valve endothelial (VEC) and 
interstitial cells (VIC) from mitral valve prolapse patients. Scale bar, 20 µm.  
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4.2 Human mitral valve endothelial cells undergo endothelial to 
mesenchymal transition 
Cells were treated for 6 and 12 days with β-glycerophosphate and ascorbic acid (βGAA) 
to induce endothelial mesenchymal transition (EndMT). We performed a quantitative PCR 
(qPCR), flow cytometric and morphological analysis to confirm that EndMT occurred after 
βGAA treatment (Figure 4.2). In particular, we observed a significant (p<0.05) upregulation of 
SMA and collagen III (Col3A1) RNA levels after 6 days of treatment (4.5±0.9 and 3.0±0.6 
fold, respectively) (Figure 4.2A). Furthermore, after 12 days of βGAA treatment, RNA analysis 
showed a significant (p<0.05) upregulation of bone morphogenetic protein 4 (BMP4) and 
collagen I (Col1A1) by 3.0±0.7 and 10.8±3.2 fold, respectively (Figure 4.2B). We also 
performed a flow cytometric analysis that underlined an overexpression of SMA on VECs 
treated with βGAA (Figure 4.2C). Finally, we observed VECs morphological changes from 
cobblestone to spindle-shape (Figure 4.2D). All these results confirmed that during βGAA 
treatment the isolated VECs underwent EndMT. 
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Figure 4.2 Endothelial to mesenchymal transition of human mitral valve endothelial cells. 
(A-B) Quantitative PCR (qPCR) of smooth muscle actin (SMA), bone morphogenetic protein 4 (BMP4), 
collagen I (Col1A1) and collagen III (Col3A1) of valve endothelial cells (VEC) in absence or in presence 
of β-glycerophosphate and ascorbic acid (βGAA) for 6 or 12 days (n = 3). (C) Flow cytometric analysis 
(FACS) of SMA for isotype control, untreated VEC, VEC treated with βGAA for 6 days and activated 
valve interstitial cells (VIC) as a positive control (n=3). (D) Phase contrast imaging of untreated VECs 
or treated for 12 days with βGAA. Magnification: 20X. * p<0.05. 
 
4.3 Endothelial to mesenchymal transition induces osteoprotegerin 
expression and secretion 
We analysed the expression of OPG in prolapsed (n = 3) and healthy mitral valve leaflets 
(n = 3). The Western blot analysis, carried out on whole tissue extract, underlined a significant 
(p<0.05) increase in prolapsed leaflets in comparison to healthy ones (Figure 4.3A and B). To 
understand better the OPG role in the MVP progression, we evaluated if VECs expressed and/or 
secreted OPG during EndMT. The experiments forcing VECs to undergo EndMT highlighted 
a significant (p<0.05) increased expression of OPG RNA levels at 6 and 12 days (1.9±0.4 and 
4.1±1.3 fold, respectively) (Figure 4.3C). In addition, implementing a commercially available 
ELISA, we observed that VECs secreted more OPG in comparison to untreated cells during the 
first 6 days of βGAA treatment (2369±564.7 pg/µg of total protein vs. 923.5±261.1 pg/µg of 
total protein, respectively; p<0.05 – Figure 4.3D).  
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Figure 4.3 Endothelial to mesenchymal transition induces osteoprotegerin expression and 
secretion. (A) Western blot of osteoprotegerin (OPG) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), as endogenous control, of mitral valve prolapse (MVP) patients and controls subjects 
(CTRL). (B) Western blot quantification using ImageJ (n=3). * p<0.05. (C) Quantitative PCR (qPCR) 
of osteoprotegerin (OPG) of valve endothelial cells (VEC) in absence or in presence of β-
glycerophosphate and ascorbic acid (βGAA) for 6 or 12 days (n = 3). (D) OPG enzyme-linked 
immunosorbent assay (ELISA) on media of untreated and βGAA treated VEC for 6 days (n=3). * 
p<0.05.  
 
 
 
52  
 
4.4 Osteoprotegerin interacts with syndecan family receptors in 
endothelial cells 
To understand better the possible directed OPG effects on endothelial cells, the first step 
was to evaluate if VECs expressed a specific receptor(s) capable of interacting with OPG and 
triggering protein expression already known to be involved in MVP. Accordingly, we carried 
out digital PCR (dPCR) analyses on nine different VEC preparations and we observed that this 
particular cell type expressed all syndecan receptors at different levels (SDC1, SDC2, SDC3 
and SCD4). As shown in Figure 4.4 the expression levels were: SDC1 2.07±0.62% with a 
precision of 2.97%; SDC2 0.41±0.05% with a precision of 5.49%; SDC3 2.42±0.50% with a 
precision of 3.50%; SDC4 1.03±0.23 with a precision of 4.85%. All the data used for the relative 
quantification are listed in Appendix A, Table A2. 
 
Figure 4.4 Syndecan expression in endothelial cells. Digital PCR (dPCR) analysis of the 
syndecan family (SDC1, 2, 3 and 4) on nine different valve endothelial cell populations. Ribosomal 
protein large P0 (RPLP0) was used as housekeeping gene. 
 
 
53  
 
To prove OPG-SDC interaction, we analysed SDC4 phosphorylation (serine 179 - 
pSDC4) upon OPG treatment. This residue is highly conserved among the family [96] and once 
it is phosphorylated the signalling cascade is shutdown [97]. We performed a Western blot 
analysis and we observed a decrement in pSDC4 at 5 and 15 minutes after OPG treatment 
(Figure 4.5A). To confirm these results, we pre-treated VECs with Heparinase I (Hep I). Hep 
I is able to inactivate the syndecans by removing the heparan sulphate domain presents in the 
extracellular portion of these receptors. As reported in Figure 4.5B, we observed the completed 
inhibition of SDC4 dephosphorilation after Hep I pre-treatment. (Figure 4.5B). The apparent 
loss of SDC4 could be due to protein destabilization after Hep I pre-treatment or the specific 
antibody used may require heparan sulphate domain to completely bind SDC4.  
 
Figure 4.5 Osteoprotegerin and Syndecan 4 in human mitral valve endothelial cells. (A) 
Western blot of phosphorylated syndecan 4 (pSDC4) and syndecan 4 (SDC4) in valve endothelial cells 
(VECs) after osteoprotegerin (OPG) treatment for 5 and 15 minutes. (n = 3). (B) Western blot of pSDC4, 
SDC4, in absence or presence of OPG or Heparinase I (Hep I) pre-treatment (5 U/ml) and OPG (n = 3).  
 
To characterize OPG signalling cascade in MVP, we evaluated extracellular signal-
regulated kinase 1 and 2 (ERK). Indeed, ERK phosphorylation upon OPG treatment has already 
been shown in chondrocytes and in endothelial cells [98, 99]. OPG successfully induced ERK 
activation and Hep I pre-treatment completely blocked this effect (Figure 4.6A). In addition, 
to verify the specificity of Hep I on SDCs we treated VECs with transforming growth factor 
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beta 1 (TGFβ-1), a recognized ERK activator, in the presence or absence of Hep I. As reported 
in Figure 4.6B, we observed that Hep I pre-treatment was not able to prevent the ERK 
activation induced by TGFβ-1 (Figure 4.6B). 
 
Figure 4.6 Osteoprotegerin, extracellular signal-regulated kinase activation and 
Heparinase I specificity in human mitral valve endothelial cells. (A) Western blot of 
phosphorylated extracellular signal-regulated kinase (pERK) and ERK, in absence or presence of 
ostoeprotegerin (OPG) or Heparinase I (Hep I) pre-treatment (5 U/ml) and OPG (n = 3). (B) Western 
blot of pERK and ERK, in absence or presence of transforming growth factor beta 1 (TGFβ-1 - 5 
ng/mL) or Hep I pre-treatment and OPG. 
 
All these results enable us to confirm that OPG interact with syndecan receptors and that 
Hep I is specific for these receptors. 
 
4.5 Osteoprotegerin induces extracellular matrix changes in 
endothelial cells 
Since isolated VECs express and activate syndecan receptors, we could investigate 
possible effects of OPG on endothelial cells. First, we checked the expression of known OPG 
downstream partners, such as integrin alpha V and beta 3 [98]. We performed a qPCR analysis 
and observed a significant (p<0.05) increase of both integrins after OPG treatments (4.4±0.9 
and 20.9±7.5, respectively; - Figure 4.7). 
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Figure 4.7 Osteoprotegerin and integrin expression in endothelial cells. Quantitative PCR 
(qPCR) of integrins alpha 5 (αv) and beta 3 (β3) of valve endothelial cells (VEC) untreated or treated 
for 12 days with 50 ng/ml of osteoprotegerin (OPG) (n=5). * p<0.05. 
 
Secondly, we evaluated several proteins such as collagens, BMP4, proteoglycans and 
metalloproteinases (MMPs) that are known to be regulated in MVP [30, 33, 93]. We identified 
a significant increase of Col1A1 (+4.0±0.6; p<0.001), Col3A1 (+3.0±0.6; p<0.01) (Figure 
4.8A), BMP4 (+2.4±0.7; p<0.05) and versican (VCAN), an extracellular matrix proteoglycan 
(+3.8±0.2; p<0.001) (Figure 4.8B). 
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Figure 4.8 Osteoprotegerin and extracellular matrix changes in endothelial cells. (A) 
Quantitative PCR (qPCR) of collagen I (Col1A1), collagen III (Col3A1), (B) bone morphogenetic 
protein 4 (BMP4) and versican (VCAN) of valve endothelial cells (VEC) untreated or treated for 12 
days with 50 ng/ml of osteoprotegerin (OPG) (n=5). * p<0.05; ** p<0.001; *** p<0.0001. 
 
To further confirm OPG effects on VECs, we evaluated total collagen production by 
colorimetric assay. We treated the endothelial cells for 48 hours in either the presence or the 
absence of OPG and we observed that treated cells secreted more collagen compared to 
untreated cells (13.4±0.7 vs. 11.3±0.4 ng of collagen / µg of total protein, respectively; p<0.05) 
(Figure 4.9A). Beside protein levels, it has been shown that MMPs activity may play an 
important role in the progression of the disease [30, 93]. We found higher MMP9 expression 
and activity after OPG treatment (Figure 4.9B and C). 
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Figure 4.9 Osteoprotegerin effects on endothelial cells. (A) Total soluble collagen produced by 
untreated or osteoprotegerin (OPG - 50 ng/ml) treated VECs for 24 and 48 hours (n = 5); * p<0.05. (B) 
Western blot and (C) gelatin zymography gel of matrix metalloproteinase 9 (MMP9) in VECs untreated 
or treated with OPG (50 ng/ml) (n = 3). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as 
endogenous control.  
 
4.6 Osteoprotegerin induces endothelial to mesenchymal transition 
To further characterize OPG effects on VECs, we investigated if OPG could drive 
EndMT. Along with increased expression of SMA and fibroblastic specific protein 1 (FSP1) 
markers, endothelial cells undergoing EndMT acquire migratory properties [14]. We observed 
a significant (p<0.05) increase of SMA (+1.6±0.2) and FSP1 (+1.9±0.3) after OPG treatments 
(Figure 4.10).  
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Figure 4.10 Osteoprotegerin induces endothelial to mesenchymal transition. Quantitative 
PCR (qPCR) of smooth muscle actin (SMA) and fibroblast specific protein 1 (FSP1) of valve endothelial 
cells (VEC) untreated or treated for 12 days with 50 ng/ml of osteoprotegerin (OPG) (n=5). * p<0.05. 
 
In addition, evaluating the percentage of the closed area in a migration assay, we showed 
that VECs under OPG stimuli (24 hours) were able to migrate faster that untreated cells (area 
closed 43.3±3.9% and 21.8±2.6% untreated cells; p<0.001 - Figure 4.11A and B). 
Interestingly, already after 6 hours, the VECs were able to migrate faster than controls (p<0.05 
– Figure 4.11A and B). 
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Figure 4.11 Osteoprotegerin induces cell migration in endothelial cells. (A) Representative 
images of wound healing assay for VECs in presence of OPG (50 ng/mL) or 10 % foetal bovine serum 
(FBS - positive control). (B) Time course representing the percentage of the area without migrating 
VECs in presence of OPG (50 ng/mL) or 10 % FBS (n = 5). * p<0.05; ** p<0.01. 
 
Furthermore, to verify whether OPG-induced VEC migration was caused by OPG-SDC 
interaction, we carried out the same migration assay in the presence of Hep I. The results 
confirmed that the VECs lost they migratory ability after Hep I pre-treatment. In particular, the 
percentage of the closed area of OPG + Hep I (26.5±3.6%) was significantly (p = 0.001) lower 
than cells treated only with OPG (43.0±3.1%) and no differences were noticed with the negative 
control (Figure 4.12A and B). 
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Figure 4.12 Osteoprotegerin, heparinase I and endothelial cell migration. (A) Representative 
images of wound healing assay for VECs in presence of OPG (50 ng/mL) with or without heparinase I 
pre-treatment (5 U/mL). (B) Bar graph depicting the percentage of migrating VECs in absence or 
presence of OPG (50 ng/ml) or heparinase I pre-treatment (5 U/mL) after 24 hours in presence of OPG 
(50 ng/mL) (n = 3). * p<0.05 vs. untreated; # p<0.05 vs. OPG treated VECs. 
 
In conclusion, together, these results showed that endothelial cell migration induced by 
OPG occurred throughout the activation of the syndecan receptors. 
 
4.7 Osteoprotegerin induces proliferation in interstitial cells and 
proteoglycan overexpression 
Since interstitial cells represent another cells type involved in the mitral valve degeneration 
[33], we also evaluated the possible OPG effects on VICs. We implemented, as well as for 
VECs, dPCR technique and we observed that all syndecan receptors are expressed at different 
levels (Figure 4.13). In particular, the expression levels were: SDC1 0.64±0.34% with a 
precision of 11.74%; SDC2 11.43±1.53% with a precision of 2.56%; SDC3 7.31±1.28% with 
61  
 
a precision of 3.61%; and SDC4 4.08±1.04 with a precision of 3.80%. All the data used for the 
relative quantification are listed in Appendix A, Table A3. 
 
 
Figure 4.13 Syndecan expression in interstitial cells. Digital PCR (dPCR) analysis of the 
syndecan family (SDC1, 2, 3 and 4) on three different valve interstitial cell populations. Ribosomal 
protein large P0 (RPLP0) was used as housekeeping gene. 
 
 A previous study [100] showed that OPG was able to increase smooth muscle cell 
proliferation but there were no data about its possible effect on interstitial cells isolated from 
human mitral valves. To test whether OPG treatment for 24 hours could induce some effects on 
VIC proliferation, we performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. The results highlighted that OPG led to a significant increase of VICs 
proliferation (22.4% increment; p value < 0.05 – Figure 4.14A). In addition, we also evaluated 
if OPG could affect VIC migratory ability. In contrast to VECs, we did not notice any 
significant variation in VIC migration under OPG stimuli (Figure 4.14B). 
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Figure 4.14 Osteoprotegerin on interstitial cell proliferation and migration. (A) Proliferation 
assay of valve interstitial cells (VIC) in absence or presence of osteoprotegerin (OPG - 50 ng/mL) for 6 
days (n = 3) * p<0.05. (B) Time course representing the percentage of the area without migrating VICs 
in absence or presence of OPG (50 ng/ml).  
 
Finally, we analysed the possible changes in RNA levels for the main proteins involved 
in the progression of mitral valve diseases [33, 81, 101]. VICs treated for 12 days with OPG 
showed a significant RNA level increment of BMP4 (+1.6±0.1; p<0.05), biglycan (BGN, 
+1.9±0.3; p<0.001), VCAN (+1.5±0.2; p<0.05), MMP2 (+1.6±0.1; p<0.01), SMA (+1.6±0.2; 
p<0.05), Col1A1 (+2.24±0.29; p<0.001) and Col3A1 (+1.58±0.29; p<0.05 - Figure 4.15). 
Interestingly, we noticed a significant upregulation of OPG (+1.5±0.2; p<0.05 – Figure 4.15).  
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Figure 4.15 Osteoprotegerin induces proteoglycan expression in interstitial cells. 
Quantitative PCR (qPCR) of bone morphogenetic protein 4 (BMP4), biglycan (BGN), versican 
(VCAN), metalloproteinase 2 (MMP2), smooth muscle actin (SMA), osteoprotegerin (OPG), collagen 
I (Col1A1) and collagen III (Col3A1) of valve interstitial cells (VIC) untreated or OPG treated (50 
ng/ml) for 6 days (n = 3). * p<0.05; ** p<0.01; ; *** p<0.001  
 
To characterize better OPG effects on VICs, we also evaluated the total collagen 
production by colorimetric assay. After 48 hours of OPG treatment ,VICs showed a significant 
increase of collagen secretion in comparison to untreated cells (18.5±0.4 vs. 16.4±0.3 ng of 
collagen / µg of total protein, respectively; p<0.05) (Figure 4.16). 
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Figure 4.16 Osteoprotegerin and collagen production in interstitial cells. Total soluble 
collagen produced by untreated or osteoprotegerin (OPG - 50 ng/ml) treated valve interstitial cells (VIC) 
for 24 and 48 hours (n = 5); * p<0.05. 
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5. HUMAN STUDY 
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5.1 Osteoprotegerin plasma levels in MVP patients with severe 
regurgitation 
Since OPG has direct effects on endothelial cells, we investigated OPG plasma levels 
in MVP patients. The analysis was carried out on 28 posterior MVP patients and 29 control 
subjects. The two groups had no statistically significant differences and the control subjects 
were selected with similar cardiovascular risk factors to MVP patients. In our population we 
observed, as previously reported [53], a positive correlation between OPG levels and age 
(Figure 5.1A).Therefore all the analysis was performed using a model adjusted for this variable. 
The main characteristics regarding all subjects are reported in Table 5.1.  
Table 5.1 Demographic characteristics in controls and MVP patients  
MVP: mitral valve prolapse. (percentage). Mean ± standard deviation  
 
We identified a significant (p<0.0001) increase of OPG plasma levels in patients with 
posterior MVP in comparison to control subjects (1953±127.5 vs. 1109±45.3 pg/mL, 
respectively; Figure 5.1B). 
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Figure 5.1 Osteoprotegerin plasma levels in patients with mitral valve prolapse. (A) Graph 
representing the correlation of osteoprotegerin (OPG) plasma levels with mitral valve prolapse (MVP) 
patients and control subjects (CTRL). (B) OPG enzyme-linked immunosorbent assay (ELISA) on 
plasma samples from control subjects or MVP patients. (Control subjects n = 29 and Mitral Valve 
Patients n = 28) *** p<0.0001. 
 
5.2 Patient characteristics 
Considering the previous results, we enrolled patients with either posterior MVP or 
anterior prolapse. The analysis was carried out on 43 MVP compared with 29 controls. Controls 
and patients were matched for age, sex, diabetes, hypertension, hypercholesterolemia and 
smoking. The two groups were comparable for all clinical and demographic features taken into 
consideretation, except for BMI and New York Heart Association (NYHA) class which were 
significantly lower (p = 0.005) and higher (p<0.001) in MVP patients than in controls (Table 
5.2) respectively. All demographic characteristics and clinical details regarding the two 
populations are summarized in Table 5.2. In addition, the pharmacological treatments were not 
significantly different between MVP and controls, except for beta-blockers, mostly taken by 
patients (Table 5.3). However, up to now, there is no evidence of any influence of this class of 
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drugs on oxidative stress levels. In all patients, blood collection was performed before coronary 
angiography and surgery, while in control subjects during a scheduled visit.  
Table 5.2 Clinical and demographic features in controls and MVP patients 
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LVEF: left 
ventricular ejection fraction; MVP: mitral valve prolapse; NYHA: New York Heart Association. 
[minimum, maximum]; (percentage); mean ± standard error. 
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Table 5.3 Drug therapies in controls and MVP patients 
MVP: mitral valve prolapse; (percentage). 
 
5.3 Osteoprotegerin levels and oxidative stress status  
We evaluated OPG plasma levels and the analysis permitted us to confirm previous 
results (1748 ± 100.2 pg/mL in patients vs. 1109 ± 45.3 pg/mL in control subjects (p<0.0001- 
Figure 5.2A). In addition, the difference between the groups remain significant (p<0.001) also 
after age- and NYHA class- adjustment. Finally, we confirmed that the oxidative stress status, 
represented by GSSG/GSH ratio, was higher in MVP patients compared to control subjects 
(0.116 ± 0.007 vs. 0.053 ± 0.013, respectively; p<0.0001 – Figure 5.2B) and remained 
significant even after NYHA class adjustment (p<0.001). Notice that no correlation has been 
found between NYHA class and OPG levels or GSSG/GSH ratio.  
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Figure 5.2 Osteoprotegerin and oxidative stress levels. (A) Osteoprotegerin (OPG) enzyme-
linked immunosorbent assay (ELISA) on plasma samples from control subjects (CTRL) and mitral valve 
prolapse (MVP) patients. (B) Ratio between oxidized (GSSG) and reduced (GSH) form of glutathione 
as oxidative stress status index in CTRL and MVP patients. 
 
5.4 Clinical predictors of mitral valve prolapse  
In order to characterize better OPG as a possible new biomarker, we took into account 
the conventional cardiovascular risk factors (age, BMI, sex, glucose, total cholesterol - Tot Col-
, triglycerides - TG -, low-density lipoprotein – LDL- and high density lipoprotein - HDL) 
performing a logistic regression method (Figure 5.3). We included in the next step only factors 
with a p ≤ 0.05 as previously published by Bursac et al. [102], indicating a possible correlation 
with MVP presence. MVP was strongly and independently associated only with BMI (p = 
0.005). Based on these evaluations and taking into account that BMI [22] levels had already 
been associated with MVP, we decided to implement a multivariable binary logistic regression 
model using these parameters. 
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Figure 5.3 Predictors of the presence of mitral valve prolapse. OR, odds ratio; CI, confidence 
interval; BMI, body mass index; Tot Col, total cholesterol; TG, triglycerides; LDL, low density 
lipoprotein; HDL, high density lipoprotein. 
 
5.5 Binary logistic regression model  
To understand better if OPG and/or GSSG/GSH ratio could be used as potential 
circulating markers of MVP, we performed a step-wise binary logistic regression model. We 
also considered BMI levels in order to obtain an improvement in specificity and sensibility. The 
regression parameters obtained from estimation procedure were β0 = 1.821, β1 = 0.005, β2 = 
36.031, β3 = -0.428 and the logistic model implemented is described in the Material and 
Methods section. This model was able to correctly classify 67 samples out of 72 (Figure 5.4). 
In addition, the logistic regression model pointed out an odds ratio of 177.7 (95%CI: 27.8-
1136.1; p<0.0001) to have MVP for subjects with p(Y_i=’MVP’) > 0.5. 
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Figure 5.4 Binary logistic regression model. Graph representing the prediction of the best binary 
logistic regression model. 
 
5.6 Osteoprotegerin as potential circulating marker of MVP 
We performed a receiver operator characteristic (ROC) curve to determine if OPG and or 
GSSG/GSH ratio together with BMI permitted us to identify MVP patients. 
As shown in Figure 5.5A, OPG and GSSG/GSH ratio had an area under ROC curve of 0.92 
(95% CI: 0.86 – 0.98) with p<0.0001; but if we combined OPG with GSSG/GSH and BMI we 
observed accuracy in terms of AUC of 0.95 (95% CI: 0.90 – 0.99) and a sensitivity of 88.4% 
(95% CI: 74.9-96.1) and a specificity of 86.2% (95% CI: 68.3 -96.1) with p<0.001 (Figure 
5.5B). 
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Figure 5.5 Osteoprotegerin combined with oxidative stress and BMI as potential 
circulating marker of MVP. Receiver operating characteristic (ROC) curves and area under the 
curve (AUC) of osteoprotegerin (OPG) combined with (A) the ratio between oxidized (GSSG) and 
reduced (GSH) form of glutathione (GSSG/GSH); (B) GSSG/GSH and body mass index (BMI). (control 
subjects n = 29, mitral valve prolapse patients n = 43; p<0.0001). 
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6. DISCUSSION 
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Mitral valve prolapse (MVP) is a frequent cause of heart failure and mortality. To date, 
pharmacological treatments are not available and surgical intervention (repair or replacement) 
is the only successful treatment.  
Our results support that endothelial to mesenchymal transition (EndMT) is a possible 
process involved in the pathogenesis of mitral valve degeneration. In addition, we showed that 
OPG may be involved in EndMT and, therefore, it could be considered as a new player in the 
disease progression. OPG is known as a decoy receptor for receptor activator of NF-κB ligand 
(RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), regulating 
multiple processes (i.e. bone resorption and cell apoptosis). In a recent review, it has been 
considered the overall knowledge regarding OPG/RANK/TRAIL axis in cardiometabolic 
disorders [53] and the possibility that OPG evaluation may be considered as a novel biomarker 
of disease complications and severity [53]. Several studies also described the relationship of 
OPG with coronary artery syndromes [46-48], aortic valve stenosis [49-51], myocardial 
infarction [52] and cardiovascular postoperative outcome [103], focusing only on the tumour 
necrosis factor superfamily.  
Interestingly, OPG is not only a decoy receptor but is also able to interact, through its 
heparin domain, with heparin-sulphate proteoglycans such as syndecan receptors [61]. This 
family is made up of four isoforms involved in different cellular processes such as apoptosis 
[61], migration, proliferation [100] and metalloproteinases (MMPs) secretion [104]. Recently, 
it has been reported that the posterior leaflet thickening, in MVP patients, is due to the formation 
of new fibrous tissue and extracellular matrix alterations [28]. In particular, MMPs [30, 93], 
bone morphogenetic protein 4 (BMP4) and VIC over proliferation [33] are involved in MVP 
progression. We show for the first time that OPG is overexpressed in MVP tissues in 
comparison to healthy subjects and that VECs are capable of producing and secreting OPG 
during EndMT. Consequently, OPG interferes with the correct valve endothelial function, 
76  
 
increases collagen deposition, overexpresses BMP4, proteoglycan and MMPs. Therefore, once 
OPG is upregulated, a vicious circle starts, potentiating valve EndMT, interstitial cell (VIC) 
activation as well as OPG self-upregulation. Overall, these results suggest a direct involvement 
of OPG in MVP pathogenesis.  
In the clinical practice, 2D-echocardiography is the only reliable clinical tool and 
circulating biomarkers are not available for the identification of this debilitating pathology. To 
the best of our knowledge, only a comparative proteomic study on plasma samples from 24 
pooled MVP patients with moderate to severe mitral regurgitation (MR), revealed reduced 
levels of haptoglobin, platelet basic protein, and complement component C4b in the MVP/MR 
patients as compared to the 24 pooled matched control cases [105]. However, the clinical 
relevance is unclear, in part because most of the identified biomarkers had moderate area under 
the receiving operating curve. Furthermore, Thalji et al. [56] and Sainger et al. [33] identified 
novel players that could be involved in myxomatous mitral valve degeneration and their data 
offer novel insights into the pathogenesis of MVP but no circulating biomarkers have been 
evaluated.  
Results of the present work show that circulating OPG and oxidative stress status, 
measured as ratio between oxidized (GSSG) and reduced (GSH) glutathione forms, are 
positively associated with severe MR due to MVP. In addition, low-normal range body-mass 
index (BMI) strongly correlated with the presence of MVP. Based on these premises, we 
developed a multivariable logistic regression model with OPG, GSSG/GSH ratio and BMI 
values. This model is able to correctly identify 95% of MVP patients and 90% of control 
subjects.  
Since all patients in the MVP group underwent surgery due to symptoms, we ruled out 
that left ventricular ejection fraction (LVEF) and heart failure (NYHA classes) were the causes 
of increased OPG plasma levels and oxidative stress status. Our data supports that severe MR, 
77  
 
due to myxomatous MVP, could be identified through this multivariable binary logistic 
regression model. 
The present study has some limitations: first of all, the exiguous number of enrolled 
patients and mitral annulus calcification (MAC) as possible confounder. However, only two 
patients in the MVP group had MAC. Since OPG is involved in many cellular processes, in 
particular calcification, further studies are needed to address also the possible implication of 
this molecule not only in patients with MAC but also in those who have mitral valve stenosis. 
Lastly, all the analysed patients had severe regurgitation due to MVP, however, additional 
studies are required to evaluate whether this model is able to discriminate mild and moderate 
regurgitation.  
 
78  
 
 
 
 
 
7. CONCLUSIONS 
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Although mitral valve prolapse is a debilitating disease, no recommended 
pharmacological treatments are available. Nevertheless, beta-blockers and angiotensin-
converting enzyme inhibitors are used to reduce valve mechanical stress reduction, thus slightly 
delaying the pathological process. Surgical intervention remains the only option when the 
regurgitation becomes severe or symptoms occur. Additionally, the mechanisms underlying the 
disease pathogenesis and progression are not fully understood. Therefore, a better 
characterization of molecular pathways may permit the identification of pharmacological 
targets capable of delaying or avoiding surgical intervention, allowing patient compliance. 
 
 
 What is the role of osteoprotegerin in mitral valve prolapse?  
Considering that endothelial to mesenchymal transition seems to be involved in mitral 
valve prolapse progression, we implemented an in vitro system able to force this process in 
isolated endothelial cells. In our experimental conditions, endothelial cells produced and 
secreted osteoprotegerin that, in turn, induced different effects on both endothelial and 
interstitial cells. In particular, we observed that osteoprotegerin, interacting with syndecan 
receptors, caused extracellular matrix changes in both cell types. Based on these results we may 
conclude that osteoprotegerin contributes to myxomatous mitral valve degeneration. 
 
 
 
 
80  
 
Mitral valve prolapse has a prevalence of over 6% in old patients (≥ 65 years). In 
addition, considering the aging population and the price of the echocardiographic evaluation, 
the health system costs may rise if pharmacological treatment or cheaper diagnosis tools are not 
identified. 
 
 
Could osteoprotegerin be used as biomarker for mitral valve prolapse?  
Our results underline that osteoprotegerin could be considered as a circulating 
biomarker for mitral valve prolapse. However, it is quite hard to believe that one single protein 
could discriminate two populations with high specificity and sensitivity. Hence, we combined 
osteoprotegerin with other markers or clinical variables. 
We performed a binary logistic regression model combining osteoprotegerin levels with 
oxidative stress status and body mass index. This model was able to correctly identify 95% of 
patients and 90% of control subjects. Finally, this approach could enable the identification of 
new signatures even for other cardiovascular diseases.  
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Table A1. Primer list.    
Primers     
GAPDH 
Fw ACA TCG CTC AGA CAC CAT G 
Rv TGT AGT TGA GGT CAA TGA AGG G 
SMA 
Fw AGA GTT ACG AGT TGC CTG ATG 
Rv CTG TTG TAG GTG GTT TCA TGG A 
COL1A1 
Fw GGA CAC AGA GGT TTC AGT GG 
Rv CCA GTA GCA CCA TCA TTT CC 
COL3A1 
Fw AGC TAC GGC AAT CCT GAA CT 
Rv GGG CCT TCT TTA CAT TTC CA 
BMP4 
Fw GAG CCT TTC CAG CAA GTT TG 
Rv CCA TCA GCA TTC GGT TAC CA 
SDC1 
Fw CTA CTA ATT TGC CCC CTG AAG A 
Rv GTC TGC TGT GAC AAG GTG AT 
SDC2 
Fw GTC TCA GAT TGA CCT TAC CAA GT 
Rv ATT GCA CCA TGA CAG CTA CA 
SDC3 
Fw GAG CCT GAC ATC CCT GAG A 
Rv GGA TTG TGG TCA GGA AGG T 
SDC4 
Fw GCA GCA ACA TCT TTG AGA GAA C 
Rv GGT ACA TGA GCA GTA GGA TCA G 
FSP1 
Fw CTC TAC AAC CCT CTC TCC TCA 
Rv GTT GAG CTT GAA CTT GTC ACC 
BGN 
Fw CAC CGG ACA GAT AGA CGT G 
Rv CCA CAT GGC GGA TGG AC 
VCAN 
Fw AAC TTC CTA CGT ATG CAC CTG 
Rv AAG TGG CTC CAT TAC GAC AG 
MMP2 
Fw TCC ACC ACC TAC AAC TTT GAG 
Rv GTG CAG CTG TCA TAG GAT GT 
OPG 
Fw AAA CAG TGA ATC AAC TCA AAA ATG TG 
Rv CTA CCA AGA CAC TAA GCC AGT 
Alpha V 
Fw ACT CTT AGC TGG TCT TCG TTT C 
Rv TGT GAG ATA CAA CTG GGC TTA C 
Beta 3 
Fw CAA GTG TGA ATG TGG CAG C 
Rv TTT TCG TCA TGT AGG GCT CC 
Fw = forward; Rv = reverse.  
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Table A2. Digital PCR of valve endothelial cells.     
Chip # of Neg (VIC) # of Neg (FAM) # qualified by QT # of Filled 
VEC5 SDC1.eds 1397 15735 15778 17025 
VEC8 SDC1.eds 3094 16069 16843 18350 
VEC7 SDC1.eds 5022 17067 17460 18814 
VEC2 SDC1.eds 2897 15283 16292 17936 
VEC3 SDC1.eds 2291 16896 17545 18656 
VEC9 SDC1.eds 516 17595 17638 18520 
VEC6 SDC1.eds 2689 16892 18460 19346 
VEC4 SDC2.eds 2623 14415 14547 17461 
VEC3 SDC2.eds 3269 17149 17267 17938 
VEC8 SDC2.eds 3764 17599 17676 19066 
VEC1 SDC2.eds 1395 16681 16809 17675 
VEC2 SDC2.eds 713 16161 16374 17834 
VEC5 SDC2.eds 1648 17678 17939 19163 
VEC7 SDC2.eds 1546 16826 16996 18033 
VEC6 SDC2.eds 3315 17465 17515 18520 
VEC9 SDC2.eds 2581 17368 17562 18522 
VEC1 SDC3.eds 1684 16756 17235 18420 
VEC4 SDC3.eds 3593 16948 17539 18155 
VEC2 SDC3.eds 2713 15469 15972 17664 
VEC5 SDC3.eds 4009 16191 17216 18092 
VEC3 SDC3.eds 5067 16767 17411 18323 
VEC5 SDC4.eds 4748 17878 18359 19236 
VEC3 SDC4.eds 1916 17606 17987 18857 
VEC4 SDC4.eds 3649 17670 17851 18816 
VEC2 SDC4.eds 1777 17194 17500 18072 
VEC1 SDC4.eds 1880 17971 18332 19043 
 
VEC = valve endothelial cell; SDC = syndecan. 
The number after VEC represents the population, while the number after SDC represent the specific receptor. 
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Table A3. Digital PCR of valve interstitial cells.    
Chip # of Neg (VIC) # of Neg (FAM) # qualified by QT # of Filled 
VIC1 SDC1.eds 7476 16449 16672 18409 
VIC2 SDC1.eds 10627 17904 17940 18594 
VIC3 SDC1.eds 1538 15934 15987 18497 
VIC3 SDC2.eds 6030 14550 17660 18423 
VIC2 SDC2.eds 11134 16927 18043 18688 
VIC1 SDC2.eds 5012 15924 17730 18385 
VIC1 SDC3.eds 7608 16005 17733 18318 
VIC3 SDC3.eds 8525 16835 17735 18627 
VIC2 SDC3.eds 10891 17314 17736 18495 
VIC3 SDC4.eds 5801 17085 17805 18647 
VIC1 SDC4.eds 4280 15692 17438 18198 
VIC2 SDC4.eds 7639 17086 17381 18404 
 
VIC = valve interstitial cell; SDC = syndecan. 
The number after VIC represents the population, while the number after SDC represent the specific receptor. 
 
